Recent trials prove unique flu fighter’s effectiveness in older adults.
Protein Sciences Corporation ushered in a new era of vaccine technology with the approval of a trivalent version of its recombinant DNA-based Flublok vaccine in 2013. A breakthrough, Flublok® was the first (and remains the only) annual flu vaccine to boast egg-free production. Consequently, it poses no risk of mutation and makes the use of infectious virus, antibiotics or formaldehyde unnecessary in production.
Protein Sciences announced that recent trial results published in the New England Journal of Medicine demonstrated Flublok® Quadrivalent, the quadrivalent version of its Flublok® influenza vaccine, “significantly improved protection” for older patients infected with the illness, as opposed to those treated by an egg-based, inactivated vaccine.
A total of 9,000 people aged 50+ were enrolled in the study, and the outcomes were staggering. The results confirmed that those administered the Flublok® Quadrivalent “were over 40% less likely to develop culture-confirmed influenza.”
Chief Medical Officer of Protein Sciences, Lisa Dunkle, explained this is significant, commenting, “Flublok® Quadrivalent, produced with modern recombinant technology can provide better protection… among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology.” She concluded that the vaccine demonstrated better protection, as she observed with, “considerably fewer people contracting the flu after vaccination with Flublok® Quadrivalent.”
Protein Sciences said its quadrivalent vaccine contains three times more active ingredients than traditional vaccines; the study also proves the vaccine produces significantly higher immune responses to the A strains of influenza (H3N2 in particular).
